Logo

CELUW

Celularity Inc.

CELUW

Celularity Inc. • NASDAQ
$0.02 ▼ -0.40% (-0.00)
Market Cap $591712
52w High $0.03
52w Low $0.02
Dividend Yield 0%
P/E -0.03
Volume 3.30K
Outstanding Shares 24.05M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $5.284M ▼ $16.166M ▼ $-23.073M ▲ -436.658% ▼ $-0.876 ▲ $-19.733M ▲
Q2-2025 $5.736M ▼ $16.358M ▼ $-24.524M ▼ -427.545% ▼ $-1.021 ▼ $-20.747M ▼
Q1-2025 $11.426M ▼ $18.358M ▼ $-19.754M ▼ -172.886% ▼ $-0.84 ▼ $-15.483M ▼
Q4-2024 $18.132M ▲ $20.069M ▲ $-13.293M ▲ -73.312% ▲ $-0.595 ▲ $-7.597M ▲
Q3-2024 $9.296M $16.94M $-16.098M -173.171% $-0.733 $-12.452M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $120K ▼ $114.239M ▼ $134.333M ▼ $-20.094M ▲
Q2-2025 $863K ▲ $120.283M ▼ $145.78M ▲ $-25.497M ▼
Q1-2025 $293K ▼ $128.876M ▼ $134.382M ▲ $-5.506M ▼
Q4-2024 $738K ▲ $132.682M ▲ $123.845M ▲ $8.837M ▼
Q3-2024 $133K $128.84M $111.56M $17.28M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-23.076M ▲ $-4.159M ▼ $0 $3.478M ▲ $-743K ▼ $-4.159M ▼
Q2-2025 $-24.524M ▼ $-998.999K ▲ $0 $1.631M ▼ $570K ▲ $-999K ▲
Q1-2025 $-19.754M ▼ $-2.993M ▼ $0 ▲ $2.32M ▲ $-673K ▼ $-2.993M ▼
Q4-2024 $-13.293M ▲ $1.594M ▲ $-1.556M ▼ $643K ▲ $681K ▲ $1.538M ▲
Q3-2024 $-16.098M $-144K $-35K $-79K $-258K $-179K

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
License Royalty and Other
License Royalty and Other
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$10.00M ▲$10.00M ▲$0 ▼
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Celularity’s income statement shows a classic early‑stage biotech profile. Revenue is still very small, coming mainly from biomaterials and biobanking rather than from its cell therapies, which are not yet commercial. Gross profit is positive but thin, meaning the current business does not yet cover the company’s broader operating costs. Operating losses and net losses have been sizable and persistent, reflecting high spending on research, clinical trials, manufacturing capabilities, and general overhead. There was a brief period of improvement, but results have swung back to meaningful losses, underlining that profitability is still a distant goal and heavily dependent on successful product development and scaling of commercial sales.

Balance Sheet

Balance Sheet The balance sheet has been shrinking, with total assets gradually declining and cash now quite limited. Debt has stayed meaningful relative to the size of the company, while the equity cushion has narrowed, leaving a relatively thin buffer to absorb future losses. The company did improve from a previously negative equity position, but that improvement has not been fully sustained. Overall, the balance sheet looks fragile: resources are modest, financial flexibility appears constrained, and further progress will likely depend on successful fundraising, partnerships, or a step‑change in commercial performance.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, which is typical for a clinical‑stage biotech but still an important risk. The company is spending more cash than it brings in from its small revenue base, and free cash flow has been consistently negative as well. Capital spending has been modest, suggesting most cash outflow is going to research, clinical trials, and operating expenses rather than large facility build‑outs. The pattern points to ongoing cash burn and a continuing need for external funding unless revenue from biomaterials and future therapies grows significantly.

Competitive Edge

Competitive Edge Celularity occupies a niche within cell and gene therapy by focusing on placental‑derived, off‑the‑shelf cell products. Its integrated model—spanning placental sourcing, biobanking, manufacturing, and product development—creates some structural advantages in control, quality, and cost. The company also has a large intellectual property portfolio and a first‑mover position in placental cell therapies, which together form a meaningful barrier to entry. However, it still operates in a very competitive landscape that includes well‑funded oncology and cell therapy players, and its competitive strength will ultimately be judged on clinical data, regulatory approvals, pricing, and the ability to win adoption versus more established approaches.

Innovation and R&D

Innovation and R&D Innovation and R&D are the core of Celularity’s story. The company is using placental tissue to develop several types of products: natural killer cell therapies, CAR‑T therapies, stromal cell therapies for immune and inflammatory diseases, and advanced biomaterials for wound and surgical care. It has built a proprietary platform (IMPACT) that covers everything from sourcing to advanced manufacturing. The pipeline is broad—oncology, Crohn’s disease, muscular dystrophy, degenerative and wound conditions—and includes both next‑generation cell therapies and potentially high‑value biomaterials. This breadth offers many shots on goal, but also means high R&D intensity, long development timelines, and substantial scientific, clinical, and regulatory uncertainty.

Summary

Celularity is an early‑stage, high‑science biotechnology company with a distinctive focus on placental‑derived therapies and biomaterials. Financially, it remains in a loss‑making, cash‑burning phase, with small but growing commercial revenue unable to offset heavy R&D and operating costs. The balance sheet is relatively thin, and continued access to capital will be important as the company advances multiple clinical programs. On the strategic side, Celularity benefits from a large patent estate, vertical integration, and a diversified portfolio that spans cell therapy, advanced biomaterials, and biobanking. The long‑term opportunity is tied to converting this scientific and platform strength into approved products and scaling commercial sales, while the main risks stem from clinical trial outcomes, regulatory milestones, funding needs, and intense competition in the broader cell and gene therapy space.